Invivyd, Inc. received a deficiency letter from Nasdaq on July 23, 2026, notifying the company that its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to meet this requirement may lead to a potential transfer to the Nasdaq Capital Market or delisting from the exchange. Invivyd intends to monitor its stock price and consider options to resolve the deficiency. Invivyd, Inc. is a biotechnology company.
